Collegium Pharmaceutical, Inc. (NASDAQ:COLL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday, July 11th.
According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “
Several other brokerages have also recently issued reports on COLL. Needham & Company LLC restated a “buy” rating and issued a $25.00 target price on shares of Collegium Pharmaceutical in a report on Wednesday, May 31st. ValuEngine upgraded shares of Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Janney Montgomery Scott reiterated a “buy” rating and set a $25.00 price target on shares of Collegium Pharmaceutical in a research note on Monday, June 12th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $22.00 price target (down previously from $24.00) on shares of Collegium Pharmaceutical in a research note on Thursday, May 11th. Three analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $21.33.
Collegium Pharmaceutical (COLL) traded up 3.19% during midday trading on Tuesday, hitting $10.34. The stock had a trading volume of 460,789 shares. The company’s 50-day moving average price is $12.14 and its 200 day moving average price is $11.95. Collegium Pharmaceutical has a 52 week low of $7.37 and a 52 week high of $20.55. The company’s market capitalization is $305.71 million.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.09. Collegium Pharmaceutical had a negative net margin of 1,319.39% and a negative return on equity of 91.05%. The company had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $4.07 million. On average, analysts expect that Collegium Pharmaceutical will post ($3.00) EPS for the current year.
WARNING: “Collegium Pharmaceutical, Inc. (COLL) Lowered to Sell at Zacks Investment Research” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2017/08/12/collegium-pharmaceutical-inc-coll-lowered-to-sell-at-zacks-investment-research-updated-updated-updated.html.
Several hedge funds have recently bought and sold shares of COLL. Morgan Stanley increased its stake in Collegium Pharmaceutical by 684.8% in the first quarter. Morgan Stanley now owns 885,268 shares of the specialty pharmaceutical company’s stock worth $8,906,000 after buying an additional 772,464 shares during the period. Massachusetts Financial Services Co. MA increased its stake in Collegium Pharmaceutical by 42.5% in the first quarter. Massachusetts Financial Services Co. MA now owns 640,189 shares of the specialty pharmaceutical company’s stock worth $6,440,000 after buying an additional 191,062 shares during the period. FMR LLC increased its stake in Collegium Pharmaceutical by 20.2% in the fourth quarter. FMR LLC now owns 915,673 shares of the specialty pharmaceutical company’s stock worth $14,257,000 after buying an additional 153,600 shares during the period. State Street Corp increased its stake in Collegium Pharmaceutical by 46.1% in the fourth quarter. State Street Corp now owns 289,219 shares of the specialty pharmaceutical company’s stock worth $4,530,000 after buying an additional 91,287 shares during the period. Finally, Leucadia National Corp acquired a new stake in Collegium Pharmaceutical during the first quarter worth $843,000. Hedge funds and other institutional investors own 82.27% of the company’s stock.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Collegium Pharmaceutical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Collegium Pharmaceutical Inc. and related companies.